Remarks/Arguments:

By this Amendment, applicants have canceled claims 15, 16, 31, 32, 35, 40, 41, 54 and 64-68, and have added new claims 69-88 to the application. Accordingly, claims 24, 26-30, 58-63 and 69-88 are presently pending in the application.

Claim Rejections - 35 U.S.C. §102

In the Office action of April 20, 2004 (Paper No. 0404), the Examiner rejected claims 15, 16, 31, 32, 64 and 65 under 35 U.S.C. §102(b) as being anticipated by Janusz (Archivum Imunologiae et Therapiae Experimentalis, 1993, Vol. 41, pp. 275-279), Zimecki (Archivum Imunologiae et Therapiae Experimentalis, 1991, Vol. 39, pp. 461-467), or Hraba (Archivum Imunologiae et Therapiae Experimentalis, 1986, Vol. 34, pp. 437-443). By this Amendment, applicants have canceled claims 15, 16, 31, 32, 64 and 65 from the application thereby rendering the prior rejection thereof moot. Applicants reserve the right to prosecute such claims in one or more continuation applications.

Claim Rejections - 35 U.S.C. §103

Also in the Office action of April 20, 2004 (Paper No. 0404), the Examiner rejected claims 15, 16, 31, 35, 40, 41, 54 and 64-68 under 35 U.S.C. §103(a) as being unpatentable over Janusz (Archivum Imunologiae et Therapiae Experimentalis, 1993, Vol. 41, pp. 275-279) in view of Zimecki (Archivum Imunologiae et Therapiae Experimentalis, 1991, Vol. 39, pp. 461-467) or Hraba (Archivum Imunologiae et Therapiae Experimentalis, 1986, Vol. 34, pp. 437-443). By this Amendment, applicants

have canceled claims 15, 16, 31, 35, 40, 41, 54 and 64-68 from the application thereby rendering the prior rejection thereof moot. Applicants reserve the right to prosecute such claims in one or more continuation applications.

Allowed Subject Matter

Claims 24, 26-30 and 58-63 were allowed in the prior Office Action.

New Claims

By this Amendment, applicants have added new claims 69-88 to the application to round out applicants' claim coverage. Claim 69 claims a method of treating a human patient afflicted with dementia comprising administering up to two therapeutic units of Colostrinin in isolated form to the human patient per day, wherein each therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms. Literal support for this claim can be found at page 6, lines 17-29 of the specification.

Claim 70 depends from claim 69 and further specifies that the up to two therapeutic units of Colostrinin in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of Colostrinin are administered to the human patient. Literal support for this claim can be found in the specification at page 6, lines 20-25. It should be noted that an "every other day" administration regimen is expressly taught in the specification at page 20, lines 17-20.

Claim 71 depends from claim 70 and further specifies that the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks. Literal support for this claim can be found in the specification at page 6, lines 23-26.

Claim 72 depends from claim 71 wherein and further specifies that a cycle of administering Colostrinin in isolated form for the first period of time followed by the second period of time when Colostrinin is administered is repeated at least once. Literal support for this claim can be found in the specification at page 6, lines 25-26.

Claim 73 depends from claim 69 and specifies that the Colostrinin is formulated for oral administration. Literal support for this claim can be found at page 7, lines 1-13.

Claim 74-78 mirror claims 69-73, except that such claims relate to a method of treating a human patient afflicted with Alzheimer's Disease rather than dementia. The literal support for such claims is identical inasmuch as the specification (e.g., at page 2, lines 14-20) teaches the administration of Colostrinin for the treatment of dementia and Alzheimer's Disease.

Claims 79-88 mirror claims 69-78, except that such claims claim a method of treating a human patient afflicted with dementia or Alzheimer's Disease comprising administering a nonapeptide having the amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO: 1) in isolated form to the patient. Literal support for these claims can be found in the specification at page 10, lines 5-13. Clearly, new claims 69-88 add no new matter to the application.

Conclusion

In view of the foregoing, applicants respectfully submit that claims 24, 26-30, 58-63 and 69-88 are presently in condition for allowance, and a timely Notice to that effect is earnestly solicited.

Respectfully submitted,

RANKIN, HILL, PORTER & CLARK, L.L.P.



Randolph E. Digges, III
Reg. No. 40,590

925 Euclid Avenue
Suite 700
Cleveland, Ohio 44115-1405
(216) 566-9700